Pfizer invests $25M into Caribou Biosciences, gets first dibs on off-the-shelf CAR-T therapy for multiple myeloma
Pfizer bought $25 million in shares of Caribou Biosciences, a Jennifer Doudna-founded biotech that uses CRISPR editing to create off-the-shelf cell therapies.
In exchange, Pfizer gets to be first at the negotiating table for Caribou’s CAR-T therapy for multiple myeloma. That therapy, CB-011, is currently in Phase I dose-expansion studies. It targets BCMA, an antigen that is over-expressed in multiple myeloma. There are two approved BCMA-targeted CAR-T therapies — J&J and Legend’s Carvykti and Bristol Myers Squibb’s Abecma — but both are autologous, meaning they use a patient’s own cells.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
